Infinity Pharmaceuticals, Inc. (INFI) Posts Q3 Loss of $0.45
Tweet
Share
E-mailGet Alerts INFI Hot Sheet
Join SI Premium – FREE
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported Q3 EPS of ($0.45), $0.05 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $23.3 million versus the consensus estimate of $22.23 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
